Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of iptacopan in aHUS phase 3 completers
CTR20243751Phase 3Active
- Sponsor
- Novartis
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Started Mar 2025; status: active.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on CTR20243751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243751.